HomeNewsBusinessStocksBiocon at new high; FDA accepts BLA for biosimilar Pegfilgrastim
Trending Topics
Sensex Live
Sapphire Foods-Devyani International Merger
Union Budget 2026
E TO E Transportation IPO
Gold Rate Today

Biocon at new high; FDA accepts BLA for biosimilar Pegfilgrastim

Biocon shares gained 2.6 percent to hit a record high of Rs 1,123 after the US health regulator USFDA has accepted pharma major Mylan's biologics licence application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim.

February 17, 2017 / 15:54 IST
Story continues below Advertisement
Remove Ad
first published: Feb 17, 2017 03:29 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin youtube
Trending Topics
Sensex Today ITC Share Price Sapphire Foods-Devyani International merger Silver Price Today Gold Rate Today Zohran Mamdani Rahul Gandhi Shah Rukh Khan Indore Water Contamination Coal India Share Price
News
Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups
Markets
Home Currencies Commodities Pre-Market IPO Global Market Bonds
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker New Fixed Deposits Fixed Deposit Comparison Fixed Income
Mutual Funds
Home MC 30 Top Ranked Funds ETFs Mutual Fund Screener
Tools
Income Tax Calculator EMI Calculator Retirement Planning Gratuity Calculator Petrol Price in India Diesel Price in India IFSC Code
Community
Stock Markets
Network 18 Sites
News18 Firstpost CNBC TV18 News18 Hindi Cricketnext Overdrive
Quick Links
About Us Contact Us Advisory Alert Advertise with Us Disclaimer Privacy Policy Cookie Policy Terms & Conditions Financial Terms (Glossary) Sitemap Investors
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.